Castrate Resistant Prostate Cancer Therapeutics Market - Growth, Trends And Forecasts (2022 - 2027)

The Castrate Resistant Prostate Cancer Therapeutics Market is segmented by Treatment Type (Chemotherapy, Hormonal Therapy, Other Treatment Types) and Geography.

Market Snapshot

Market Snapshot1
Study Period: 2017-2025
Base Year: 2021
Fastest Growing Market: North America
Largest Market: Asia Pacific
CAGR: 6.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Castrate Resistant Prostate Cancer Therapeutics Market is expected to register a CAGR of 6.5% during the forecast period. The major factors driving the growth of the market include growing aging population and rising prevalence of castrate-resistant prostate cancer, increasing technological advancements and increasing government initiatives for cancer awareness.

Furthermore, growing adoption of novel drugs, along with an unhealthy lifestyle are key factors anticipated to accelerate market growth. The need for faster treatment options and investments in R&D by key players is also fueling the growth rate of the market.

According to a researh article by Nicolas H Thurin et al., published in Cancer epidemiology 2020, the prevalence and incidence of metastatic castration-resistant prostate cancer (mCRPC) in France were estimated as 62 and 21 cases per 100,000 population. In addition, maximum metastatic castration-resistant prostate cancer (mCRPC) incidence was in men who were aged 80-89 (175 per 100,000 population). Thus, owing to above mentioned factors it is expected to drive market growth over the forecast period.

Scope of the Report

As per scope of the report, castration-resistant prostate cancer is a disease progression which may be due to rise in serum prostate-specific antigen, progression of pre-existing disease, and appearance of new metastases. The Castrate Resistant Prostate Cancer Therapeutics Market is segmented by treatment type and geography.

By Treatment Type
Hormonal Therapy
Radiation Therapy
Other Treatment Types
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Hormonal Therapy Segment is Expected to Hold a Significant Market Share over the Forecast Period.

The major factors driving the growth of the segment include rising geriatric population who are more prone to castrate resistant prostate cancer, launch of new drugs, presence of high number of approved drugs and the expansion of product indication. In addition, the rising development of innovative drugs to address unmet needs and current treatment options is expected to boost the growth of the market for castrate-resistant prostate cancer.

According to a National Clinical Trial (NCT) Registry, Sir Mortimer B. Davis Jewish General Hospital is currently conducting a phase II clinical trial with a new generation of hormonal therapy Darolutamide to assess the response of stereotactic body radiation therapy (SBRT) layered on Darolutamide (BAY1841788) on radiological progression-free survival (RPFS) and deferring palliative second line systemic therapy in patients with castration resistant prostate cancer. The trial began in October 2020 and expected to complete in November 2027.

Thus, increasing research and development activities along with rising prevalence of castrate resistant prostate cancer due to aging population is expected to drive the market growth.

key trend 1.png

North America Region is Expected to Hold a Major Market Share Over the Forecast Period

In North America region, the United States is expected to hold signifcant market share due to high prevalence of the disease, the presence of major market players, increasing research and development activities and favorable reimbursement policies.

In June 2020, in United States, Exelixis, Inc in collaboration with Roche-Genentech and Takeda initiated a phase III clinical trial to evaluate the safety and efficacy of cabozantinib in combination with atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC).

Furthermore, presence of favorable reimbursement policies for patients is expected to boost the growth of the market for castrate-resistant prostate cancer. For instance, Jevtana is covered under Medicare Part B benefits. It is identified by J9043 and C9276 under Healthcare Common Procedure Coding System. Thus, owing to above mentioned factors, market in the United States is expected to be one of the largest and is also expected to grow in the future.​

castrate resistant geo stats.PNG

Competitive Landscape

The Castrate Resistant Prostate Cancer Therapeutics Market is consolidated competitive and consists of few major players. In terms of market share, few of the major players currently dominate the market. Some of the market players include Sanofi, Johnson & Johnson, Pfizer, Inc, Bayer AG, Dendreon Pharmaceuticals LLC and others.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Aging Population and Rising Prevalence of Castrate-resistant Prostate Cancer

      2. 4.2.2 Increasing Technological Advancements

      3. 4.2.3 Increasing Government Initiatives for Cancer Awareness

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Castrate-resistant Prostate Cancer Drugs

      2. 4.3.2 Low Success Rate of Clinical Trials

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment Type

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Hormonal Therapy

      3. 5.1.3 Radiation Therapy

      4. 5.1.4 Other Treatment Types

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Sanofi

      2. 6.1.2 Pfizer Inc

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 Bayer AG

      5. 6.1.5 Dendreon Pharmaceuticals LLC

      6. 6.1.6 AstraZeneca Plc

      7. 6.1.7 Kintor Pharmaceutical Limited

      8. 6.1.8 Clovis Oncology

      9. 6.1.9 Glaxosmithkline Plc

      10. 6.1.10 Aragon Pharmaceuticals, Inc

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Castrate Resistant Prostate Cancer Therapeutics Market market is studied from 2017 - 2025.

The Castrate Resistant Prostate Cancer Therapeutics Market is growing at a CAGR of 6.5% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia Pacific holds highest share in 2019.

Sanofi, Johnson & Johnson, Bayer AG, Dendreon Pharmaceuticals LLC, Pfizer Inc are the major companies operating in Castrate Resistant Prostate Cancer Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!